Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Lawrence Gordon (NPI 1982609665)

Field	Value
Entity Type	Individual
Organization	Lawrence Gordon
Address	6005 Park Ave
City	Memphis
State	TN
ZIP	38119
Taxonomy	Ophthalmology Physician
NPI Enumerated	June 17, 2005

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

LAWRENCE GORDON’s Medicare billing profile is that of a medical-retina practice focused on intravitreal pharmacotherapy and retinal imaging: the top revenue drivers are injections and retinal diagnostics (J0178, J2777, Q5128 and 92134), and the list also includes comprehensive and established ophthalmology visits (92014) and procedure codes for vitreous procedures (67028). The code mix — dominated by high-volume anti-VEGF and newer retina drugs — indicates day-to-day operations centered on recurring injection visits and frequent imaging follow-up rather than primary care ophthalmology alone.

Revenue concentration is high: this provider has $2.9M in total Medicare revenue and the precomputed top 3 Medicare codes by revenue account for 71.2% of that Medicare revenue. Those top three contributors are J0178 ($1.4M, 48.0%), J2777 ($431.5K, 14.9%), and Q5128 ($238.4K, 8.2%), showing most Medicare dollars come from a small set of intravitreal drug administrations.

Payer mix is effectively single-payer: Medicare revenue is $2.9M while Medicaid billing is listed as none, so the provider has no Medicaid activity on file. This concentration means the practice’s public-payer exposure is highly dependent on Medicare policy and utilization trends, with little diversification into state Medicaid revenues.

Competitive standing is mixed by service line: for the primary drug J0178 the provider ranks #521 of 3204 (84th percentile) which is a solid national position but characterized as "typical, unremarkable volume" for that code; by contrast the provider is an outlier on diagnostic retinal imaging, with 92134 ranking #304 of 26868 (99th percentile) and labeled an "extreme outlier, far above typical national volume," indicating unusually high imaging throughput versus peers. Procedure-level rankings for injection-related and imaging services (67028 ranks #240 of 4255, 94th percentile, "notably above typical national volume"; 92014 ranks #1184 of 35415, 97th percentile, "notably above typical national volume") further support a strong local/national footprint in retinal procedures and follow-up care.

The practice bills a mix of branded biologics, newer agents, and biosimilars: J0178 (aflibercept) is the largest single revenue driver, J2777 (faricimab) is the second-largest, and Q5128 (ranibizumab-eqrn biosimilar) is also a top contributor. This drug mix—high shares from both established and newer intravitreal agents—suggests active adoption of contemporary retina therapeutics and potentially frequent, recurring treatment visits tied to drug regimens.

There is evidence of procedural breadth beyond injections: the provider bills for vitrectomy/ILM procedures (67042: 16 claims, $13.6K, ranks #692 of 1087, "typical, unremarkable volume") and retinal laser (67228: 31 claims, $7.1K, ranks #212 of 648, "typical, unremarkable volume"). These lower-volume but higher-complexity codes imply capability to perform surgical retinal interventions in addition to medical retina care.

Use of non-specific drug code activity and implants is notable at a secondary level: J3490 (unclassified drugs) accounts for $97.2K (3.4% of Medicare revenue) with 47 claims (rank #1701 of 2838, "typical, unremarkable volume"), and J7312 (dexamethasone implant) contributes $75.2K (2.6% of Medicare revenue) and ranks #56 of 492 (87th percentile, "typical, unremarkable volume"). These entries suggest episodic use of other intravitreal therapies and occasional reliance on unclassified drug billing.

The provider has an established enrollment history — NPI enumerated 2005-06-17 (~21 years ago) — which supports interpretation of the observed high imaging and injection volumes as the output of a long-standing practice and referral network rather than a newly opened clinic. At the same time, the heavy reliance on a small set of intravitreal drug codes (top 3 = 71.2%) combined with no Medicaid billing on file represents both an operational specialization and a revenue concentration risk if utilization or reimbursement for those codes changes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

19 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	2,030	$690	$1.4M
J2777	Injection, faricimab‑svoa, 0.1 mg	14,880	$30	$431.5K
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	1,110	$210	$238.4K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,330	$90	$205.2K
J2781	Injection, pegcetacoplan, intravitreal, 1 mg	1,070	$120	$127.8K
J3490	Unclassified drugs	50	$2,070	$97.2K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	1,160	$80	$95.4K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	3,270	$30	$94.7K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	480	$160	$75.2K
J9035	Injection, bevacizumab, 10 mg	1,100	$50	$59.5K

Showing 1–10 of 19

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Lawrence Gordon — 3 of 19 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

19 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	14	80	790	$680	$769.8K
J2777	26	50	15,060	$30	$592.1K
Q5128	10	20	1,190	$210	$394K
67028	9	80	1,130	$90	$98.5K
J2781	3	20	560	$120	$82.5K
J7312	3	10	210	$150	$45.8K
J3490	42	60	70	$400	$41.9K
67042	30	40	20	$1,020	$34.5K
92014	24	810	120	$80	$19.2K
J9035	4	70	140	$50	$17.1K

Showing 1–10 of 19

Related Providers

Other providers that share a Tax Identification Number (TIN) with Lawrence Gordon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tawan Khamapirad	TN	Ophthalmology Physician	$3.4M	$4.2K
William Priester	TN	Ophthalmology Physician	$3.2M	$0
Richard Sievers	TN	Ophthalmology Physician	$2.5M	$0
Steven Williams	TN	Retina Specialist (Ophthalmology) Physician	$2.1M	$0
Calvin Brown	MS	Ophthalmology Physician	$1.2M	$0

Nearby Providers

Other providers in the same ZIP code as Lawrence Gordon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ut Medical Group Inc	TN	Multi-Specialty Clinic/Center	$0	$53.1M
Amisub (sfh), Inc.	TN	General Acute Care Hospital	$0	$20.2M
Maxim Healthcare Services, Inc.	TN	Home Health Agency	$0	$18.5M
Mid-south Maternal Fetal Medicine PC	TN	Maternal & Fetal Medicine Physician	$0	$8.1M
Elect Home Care, LLC	TN	In Home Supportive Care Agency	$0	$7.6M
First Choice Community Services, Inc	TN	In Home Supportive Care Agency	$0	$7.5M
Tennessee Emergency Physicians, PLLC	TN	Emergency Medicine Physician	$0	$6.3M
Dar Salud Care PLLC	TN	Family Medicine Physician	$0	$5.2M
Silver Angels Of Tennessee - Shelby, LLC	TN	In Home Supportive Care Agency	$0	$5.1M
Abundant Care LLC	TN	In Home Supportive Care Agency	$0	$4.1M

Lawrence Gordon — Billing Profile & Reimbursement Data

Sign up for Lawrence Gordon — Billing Profile & Reimbursement Data policy alerts

Lawrence Gordon — Billing Profile & Reimbursement Data

Sign up for Lawrence Gordon — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References